Distinct MRI pattern of “pseudoresponse” in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review-Reference-Cited by-同舟云学术

Distinct MRI pattern of “pseudoresponse” in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review

Published:2021-08 Issue:8 Volume:9 Page:
ISSN:2050-0904
Container-title:Clinical Case Reports
language:en
Short-container-title:Clin Case Rep

Author:

Gatto Lidia¹,Franceschi Enrico¹^ORCID,Tosoni Alicia¹,Di Nunno Vincenzo¹,Maggio Ilaria¹,Tonon Caterina²,Lodi Raffaele²,Agati Raffaele²,Bartolini Stefania¹,Brandes Alba Ariela¹^ORCID

Affiliation:

1. Department of Medical Oncology Azienda USL of Bologna Bologna Italy

2. IRCCS Istituto delle Scienze Neurologiche di Bologna Bologna Italy

Publisher

Wiley

Subject

General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ccr3.4604

Reference30 articles.

1. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015

2. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

3. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

4. Glioblastoma and Other Malignant Gliomas

5. EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness;Expert Reviews in Molecular Medicine;2024

2. Bevacizumab in real-life patients with recurrent glioblastoma: benefit or futility?;Journal of Neurology;2023-02-22

3. Characterization of Glioblastoma Cells Response to Regorafenib;Cancers;2022-12-15

4. Regorafenib/temozolomide;Reactions Weekly;2022-10-01

5. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes;Frontiers in Radiology;2022-02-25